Bio-Rad Laboratories, Inc. J.P. Morgan Healthcare Conference 2019 - PowerPoint PPT Presentation

Bio-Rad Laboratories, Inc. J.P. Morgan Healthcare Conference 2019

Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our investment in high growth emerging markets and new products and technologies, our new focus on lab to clinic solutions, improvements to our operational efficiency and our future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “anticipate,” “believe,” “expect,” “assume,” “continue,” “may,” “will,” “intend,” “estimate,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. These statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such factors include, but are not limited to, recent changes to our global organizational structure and executive management team, difficulties in implementing our global ERP system, our ability to develop and market new or improved products according to our business plan, currency fluctuations and other factors discussed in more detail in our recent filings with the Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect our views and assumptions only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements. Advance discovery. Improve lives.

Bio-Rad Today Continuous 65+ Innovation A History of Contribution Years Strong Performance Key Competencies $2.2B+ Fueling Ongoing Growth Annual Sales Complementary 8,300+ Business Mix Employees Worldwide Leveraging Across the Company Advance discovery. Improve lives.

Bio-Rad Global Profile Applied 3 % BioPharma Asia 11 % 21 % EMEA 35 % Hospital Labs 38 % Academic 23 % Customers Geography Products Transfusion Labs Reference Labs Americas 12 % 13 % 44 % Diversified Customer Base Worldwide Presence Broad Product Base Advance discovery. Improve lives.

A History of Innovation 2012 1982: First commercial Bio-Rad launches the 1967: Bio-Rad launches first T-4 test for Hemoglobin A1c droplet digital PCR by column test revolutionizing system Thyroid testing 2006 : Place first multiplex immunoassay system BioPlex 2200 2000 Launched the first 4- color real time PCR platform on the market 2017 Bio-Rad launches the first digital PCR CE-IVD test to monitor levels of 1972 BCR-ABL in cancer Electrophoresis grade chemicals are introduced Advance discovery. Improve lives.

Leadership Positions Autoimmune DNA amplification Bio-Chromatography Diabetes Market Focus Infectious Disease Electrophoresis Blood Typing Gel image Quality Control Protein Assay Digital Biology Advance discovery. Improve lives.

Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions Translational Research Continuum Discovery Development Production Treatment & follow up • • • • Basic disease Target validation Clinical studies Treatment • • mechanism Lead development Regulatory planning and • research of a therapy and/or Drug and/or monitoring • • Pathway research diagnostics diagnostics mfg. & Post-market • • Target surveillance Pre-clinical studies commercialization identification Genomics, Cell Biology, Proteomic, Software & Informatics Advance discovery. Improve lives. 7 - Bio-Rad Confidential -

Life Science Profile Highlights  Market Size: $45B – 50B  Market Growth 4% CAGR  Addressable Market: $8 – 9B Asia 26 % Americas 43 % Applied Markets Research Revenue Consumables 7 % 63 % 48 % Geography Customer Products Segments EMEA 31 % Instruments/ BioPharma Apparatus 30 % 52 % Source: Bio-Rad Internal Advance discovery. Improve lives. 8

Life Science Solutions Gene Transfer Genotyping & Gene Protein Purification & Modulation Expression (chromatography) (PCR & qPCR) Protein Expression (multi-analyte detection) Multi-omics Solutions Digital Biology (Droplet Digital PCR, ddSeq) Protein Quantification (western blotting) Cellular Imaging Antibodies Cell Sorting & Analysis Advance discovery. Improve lives. 9

Cell Biology New Entrant in Growing Market  Flow Cytometry Cell Sorters and Analyzers Flow Cytometry  Cell Imagers and Counters Antibodies TC20 Automated  Flow Cytometry Reagents & Assays Cell Counter  Flow Cytometry Antibodies S3e Cell Sorter ZOE Fluorescent Cell Imager ZE5 Cell Analyzer 10 Advance discovery. Improve lives.

Digital Biology Leadership Position • ddPCR technology • Broad IP portfolio • Broad application from research to therapeutics • Rapid development of new applications Advance discovery. Improve lives.

Clinical Diagnostics Profile Highlights  Market Size: $55-60B Asia 19 %  Addressable Market: $5.5B  Market Growth ~ 5% EMEA 39 % Instruments 25 % Revenue Transfusion Geography Laboratory 18 % Customer Products Segments Americas Hospital 42 % Laboratory 61 % Reference Laboratory Reagents 21 % 75 % Source: Bio-Rad Internal Advance discovery. Improve lives. 12

Clinical Diagnostics Diagnostic Testing Protecting the Quality and Monitoring Blood Supply Assurance  Diabetes  Blood Typing  Quality Controls  Infectious Disease  Blood Virus Screening  Quality Assessments  Autoimmune  HIV Confirmation Testing  Data Management  Transfusion Compatibility 13 Advance discovery. Improve lives.

Blood Typing Highlights  Bio-Rad #2 in Market  3,000+ Automated Systems Placed Gel Cards  Unrivalled Results Management  Broadest portfolio for safe transfusions Tango infinity Geographic Expansion  IH-1000 and Infinity FDA Approvals  IH-Com and Manual Systems Approval  Growing Demand in Emerging Markets IH-Com & IH-Web Results Management IH-500 (Coming soon to the US) IH-1000 Advance discovery. Improve lives. 14

Portfolio Expansion Near Term Focus • Core Market Enhancement • Microbiome • Point of Care • Non-Invasive Prenatal Testing Advance discovery. Improve lives.

The Importance Of Clinical Diagnostics In Healthcare Targeted Disease Prevention Early Disease Detection Accelerated Diagnostics Targeted Therapy Earlier detection saves lives Improved • Lowers total costs Outcomes • Reduces risks • Increases satisfaction • Improves treatment efficiency Advance discovery. Improve lives. 16

Diabetes Diabetes is an accelerating global problem. Advance discovery. Improve lives. 17

Bio-Rad Pioneered HbA1c Testing Bio-Rad provides HbA1c testing solutions for all segments, leading to better outcomes for patients with diabetes. Small Labs / Medium Labs Large Labs Clinics D-10 VARIANT II D-100 Advance discovery. Improve lives. 18

Cancer The global cancer burden continues to rise, with 18 million new cases and over 9 million deaths in 2018. Early Detection Is Key To Survival Advance discovery. Improve lives. 19 * Cancer Research UK

Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy Bio- Rad products enable monitoring of a patient’s response to targeted therapy. Systems Consumables Menu For customers developing Droplet digital PCR Large portfolio of assays and validating tests platforms Advance discovery. Improve lives. 20

Translational Discovery to Diagnostics Production Discovery  Clinical studies  Basic disease mechanism research  Regulatory  Pathway research Translational  Drug and/or diagnostics  Target identification manufacturing and Medicine commercialization Development Therapies  Target validation  Treatment planning and monitoring  Lead development of a therapy and/or diagnostics  Post-market surveillance  Pre-clinical studies Advance discovery. Improve lives.

Operational Transformation Building a Scalable Model Advance discovery. Improve lives.

The Opportunity Rationalize Manage Leverage Global Footprint Procurement ERP Investment  Consolidate distribution  Centralized Procurement  Increase visibility centers  Global price concessions  Optimize inventory levels  Close redundant  Targeted reduction in  Improve service commercial sites direct and indirect  Reduce scrap  Increase Asia purchases  Lower project overhead manufacturing 23 Advance discovery. Improve lives.

The Path Forward  Geographic Expansion  Optimized Supply Chain  New Products  Reduced ERP Spend  New Markets  Shared Services Driving Expanding Revenue EBITDA  Operating Leverage Growth Margins Creating Accelerating  Increased Cash Flow  Higher Profitability Shareholder Free Cash  Reduced CAPEX  Disciplined Capital Value Flow Allocation  Tax Savings Key Contributions to Value Creation 24 Advance discovery. Improve lives.

Summary – Closing Remarks  Investments at an inflection point  Building on our market and product leadership  Increased focus on acquisition opportunities  Leveraging our new organization, operating model and systems to drive value Advance discovery. Improve lives.

Bio-Rad Laboratories, Inc. J.P. Morgan Healthcare Conference 2019